Quotable: Top Experts On Policy Hot Topics

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Quotable
Source: Shutterstock

“We have to have an open and honest discussion about whether the guard rails are really appropriate for a country like Germany, because we’ve seen innovative products opting out from Germany and this is not the way to go.” – EUCOPE’s Alexander Natz discusses a new German law and flaws in the country’s pricing system. Find out more: New German Research Law Fails To Stop Companies From Opting Out Of The Market

“I think that part of the fear of conflict of interest is the idea that everything is going on behind closed doors. So, the more we can bring into the public domain, the more we can have these debates in public.” – The European Medicines Agency’s Emer Cooke on the need for transparency when managing conflicts of interest. Find out more:

More from International

More from Pink Sheet

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.